These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 883559)

  • 21. Role of dopamine in schizophrenia and Parkinson's disease.
    Birtwistle J; Baldwin D
    Br J Nurs; 1998 Jul 23-Aug 12; 7(14):832-4, 836, 838-41. PubMed ID: 9849144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance.
    Kumar AM; Ownby RL; Waldrop-Valverde D; Fernandez B; Kumar M
    J Neurovirol; 2011 Feb; 17(1):26-40. PubMed ID: 21165787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct gradients of various neurotransmitter markers in caudate nucleus and putamen of the human brain.
    Hörtnagl H; Pifl C; Hörtnagl E; Reiner A; Sperk G
    J Neurochem; 2020 Mar; 152(6):650-662. PubMed ID: 31608979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-mortem distribution of dopamine and homovanillic acid in human brain, variations related to age, and a review of the literature.
    Adolfsson R; Gottfries CG; Roos BE; Winblad B
    J Neural Transm; 1979; 45(2):81-105. PubMed ID: 381583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group.
    LeWitt PA; Galloway MP; Matson W; Milbury P; McDermott M; Srivastava DK; Oakes D
    Neurology; 1992 Nov; 42(11):2111-7. PubMed ID: 1436520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia.
    Bird ED; Spokes EG; Iversen LL
    Brain; 1979 Jun; 102(2):347-60. PubMed ID: 455044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brain-noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome.
    Riederer P; Birkmayer W; Seemann D; Wuketich S
    J Neural Transm; 1977; 41(4):241-51. PubMed ID: 925685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meige syndrome in the spectrum of Lewy body disease.
    Mark MH; Sage JI; Dickson DW; Heikkila RE; Manzino L; Schwarz KO; Duvoisin RC
    Neurology; 1994 Aug; 44(8):1432-6. PubMed ID: 8058144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine and depression: a review of recent evidence. I. Empirical studies.
    Willner P
    Brain Res; 1983 Dec; 287(3):211-24. PubMed ID: 6140979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine metabolism increases in post-mortem schizophrenic basal ganglia.
    Toru M; Nishikawa T; Mataga N; Takashima M
    J Neural Transm; 1982; 54(3-4):181-91. PubMed ID: 6127373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Homovanillic acid concentrations in brain, CSF and plasma as indicators of central dopamine function in primates.
    Elsworth JD; Leahy DJ; Roth RH; Redmond DE
    J Neural Transm; 1987; 68(1-2):51-62. PubMed ID: 3806086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "In vivo" release of endogenous neurotransmitters in cat limbic regions: effect of chlorpromazine and of electrical stimulation.
    Stadler H; Ciria MG; Bartholini G
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 288(1):1-6. PubMed ID: 240128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus.
    Cash R; Dennis T; L'Heureux R; Raisman R; Javoy-Agid F; Scatton B
    Neurology; 1987 Jan; 37(1):42-6. PubMed ID: 3796837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alterations in norepinephrine and dopamine content in selected brain areas of guinea pigs adapted to simulated high altitude.
    Light KE; Shetlar D; Strahlendorf JC; Hughes MJ; Barnes CD
    J Neurochem; 1981 Feb; 36(2):773-5. PubMed ID: 7463091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitivity to ageing of the limbic dopaminergic system: a review.
    Barili P; De Carolis G; Zaccheo D; Amenta F
    Mech Ageing Dev; 1998 Dec; 106(1-2):57-92. PubMed ID: 9883974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopamine in schizophrenia.
    Heritch AJ
    Am J Psychiatry; 1992 Nov; 149(11):1620-1. PubMed ID: 1415847
    [No Abstract]   [Full Text] [Related]  

  • 37. Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders.
    Fernández-Ruiz J; Hernández M; Ramos JA
    CNS Neurosci Ther; 2010 Jun; 16(3):e72-91. PubMed ID: 20406253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of cerebral dopaminergic systems by noise and whole-body vibration.
    Nakamura H; Moroji T; Nohara S; Nakamura H; Okada A
    Environ Res; 1992 Feb; 57(1):10-8. PubMed ID: 1740092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Seasonal variation in human central dopamine activity.
    Karson CN; Berman KF; Kleinman J; Karoum F
    Psychiatry Res; 1984 Feb; 11(2):111-7. PubMed ID: 6584933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine receptors mediate strategy abandoning via modulation of a specific prelimbic cortex-nucleus accumbens pathway in mice.
    Cui Q; Li Q; Geng H; Chen L; Ip NY; Ke Y; Yung WH
    Proc Natl Acad Sci U S A; 2018 May; 115(21):E4890-E4899. PubMed ID: 29735678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.